Novo Nordisk Faces Setback in Kidney Disease Drug Trial
A key drug trial for Novo Nordisk's kidney disease treatment did not meet its main goal, impacting future sales.
Novo Nordisk recently faced a challenge. Its new drug, ziltivekimab, aimed to treat chronic kidney disease. The company had high hopes for this medicine, expecting it to bring in large sales.
However, a late-stage study, called a Phase 3 trial, did not go as planned. The drug missed its main target. This means it did not show the expected benefits for patients in this study.
This news is a setback for Novo Nordisk. Analysts had predicted the drug could earn billions. It was also meant to help the company offer a wider range of medicines.
Novo Nordisk still has other studies underway. These are named Artemis and Hermes. The company hopes these trials can still prove the drug's value. Investors and patients will watch these next steps closely.
Source: FierceBiotech
More from Biotech
